Similar Early Complication Rate in Simultaneous Pancreas and Kidney Recipients on Tacrolimus/Mycophenolate Mofetil Versus Tacrolimus/Sirolimus Immunosuppressive Regimens

References 

1. Stratta RJ. Surgical nuances in pancreas transplantation. Transplant Proc. 2005;37:1291
   • Abstract
   • Full Text
   • Full-Text PDF (56 KB)
   • CrossRef
2. Bindi ML, Biancofiore G, Meacci L, et al. Early morbidity after pancreas transplantation. Transpl Int. 2005;18:1356
   • MEDLINE
   • CrossRef
3. Gruessner AC, Sutherland DE. Pancreas transplant outcomes for United States (US) cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR). Clin Transpl. 2008;45:
4. Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplant. 2009;87:233
5. Dean PG, Lund WJ, Larson TS, et al. Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplant. 2004;77:1555
6. Arbogast H, Malaise J, Illner WD, et al. Rejection after simultaneous pancreas-kidney transplantation. Nephrol Dial Transplant. 2005;20(suppl 2):ii11
   • CrossRef
7. Steurer W, Malaise J, Mark W, et al. Spectrum of surgical complications after simultaneous pancreas-kidney transplantation in a prospectively randomized study of two immunosuppressive protocols. Nephrol Dial Transplant. 2005;20(suppl 2):ii54
   • CrossRef
8. Malaise J, De Roover A, Squifflet JP, et al. Immunosuppression in pancreas transplantation: the Euro SPK trials and beyond. Acta Chir Belg. 2008;108:673
9. Teutonico A, Schena PF, Di Paolo S. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol. 2005;16:3128
   • MEDLINE
   • CrossRef
10. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000;343:230
    • MEDLINE
    • CrossRef
11. Phung TL, Ziv K, Dabydeen D, et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell. 2006;10:159
12. Troppmann C, Pierce JL, Gandhi MM, et al. Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: a matched-pair pilot study. Transplant. 2003;76:426
13. Berney T, Secchi A. Rapamycin in islet transplantation: friend or foe?. Transpl Int. 2009;22:153
    • CrossRef
14. Gruessner AC, Sutherland DE. Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of October 2002. Clin Transpl. 2005;41:2002
15. Benedetti E, Gruessner AC, Troppmann C, et al. Intra-abdominal fungal infections after pancreatic transplantation: incidence, treatment, and outcome. J Am Coll Surg. 1996;183:307
    • MEDLINE
16. Stratta RJ, Shokouh-Amiri MH, Egidi MF, et al. A prospective comparison of simultaneous kidney-pancreas transplantation with systemic-enteric versus portal-enteric drainage. Ann Surg. 2001;233:740
    • MEDLINE
    • CrossRef
17. Sandrini S, Setti G, Bossini N, et al. Steroid withdrawal five days after renal transplantation allows for the prevention of wound-healing complications associated with sirolimus therapy. Clin Transplant. 2009;23:16
    • CrossRef
18. Burke GW, Gaynor JJ, Sageshima J, et al. Lower rate of acute rejection with rapamycin vs mycophenolate mofetil in simultaneous pancreas-kidney transplanta recipients: 8-year follow-up. CG Xenotransplant. 2009;16:400